CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05211336
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:41.507513+00:00
- Published At
- 2025-04-20T00:00:00+00:00
- Record Updated At
- 2026-01-08
- Results Posted At
- 2025-04-20
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)", "Aggressive B-cell Lymphoma With Secondary Involvement of the CNS"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-08"- protocolSection.identificationModule.nctId
"NCT05211336"- protocolSection.identificationModule.officialTitle
"Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (VIPOR) for Diffuse Large B-cell Lymphoma Involving the Central Nervous System"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-04-20"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.